disease activity

December 13, 2017December 13, 2017

Levels of Nerve Protein in Blood Provide Good Grasp of MS Activity, Study Finds

News

Blood levels of the nerve damage marker neurofilament light provide a reliable picture of multiple sclerosis activity in both the relapsing-remitting and progressive forms of the ... Read more

December 4, 2017December 14, 2017

Blood Test That Helps Predict MS Disease Activity Might Lower Need for MRI Scans, Study Suggests

News

A blood test may someday replace some of the magnetic resonance imaging (MRI) scans taken by people with multiple sclerosis (MS)  — offering an easy, cheap ... Read more

August 31, 2017August 31, 2017

Tecfidera Shows Promise as Replacement MS Therapy for Tysabri, Study Shows

News

Tecfidera (dimethyl fumarate) can be a suitable replacement therapy when Tysabri (natalizumab) is discontinued, keeping low levels of disease activity in patient with relapsing-remitting multiple sclerosis (RRMS), according ... Read more

July 14, 2017July 15, 2017

High Levels of Pro-Inflammatory Immune Cells in Intestines May Promote MS Activity, Study Reports

News

People with multiple sclerosis have high levels of pro-inflammatory TH17 immune cells in their intestines that correlate with change in the micro-organism mix in their gut ... Read more

May 31, 2017May 31, 2017

#CMSC17 – Lemtrada’s 2 Year Therapy in RRMS Sustains Efficacy for Over 6 Years Without Additional Treatment

News

Taking Lemtrada (alemtuzumab) for two years inhibited magnetic resonance imaging (MRI) disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) for more than six years, the CARE-MS I ... Read more

May 30, 2017May 30, 2017

#CMSC17 – Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying Treatments

News

Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after five years may safely discontinue their ... Read more

March 28, 2017April 24, 2017

FDA Approves Ocrevus as 1st MS Treatment for Both Relapsing and Primary Progressive Forms

News

At long last, and for the first time in medical history, people with both relapsing and primary progressive forms of multiple sclerosis have reason to celebrate. The ... Read more

March 28, 2017May 2, 2017

Ocrevus’ Journey from Defiant Idea to Game-Changing Treatment

News

Twenty years ago, the idea that B-cell depletion could treat multiple sclerosis would have been greeted with a hearty laugh by any well-respected neurologist or MS researcher — or ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Smoking Significantly Worsens Quality of Life for MS Patients, Study Shows

News

Multiple sclerosis (MS) patients who smoke have a significantly worse quality of life than non-smoking MS patients, concludes a new study. Researchers presented the study, “Smokers with MS ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Ocrevus Significantly Decreases Disease Activity in MS Patients, Study Shows

News

Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with multiple sclerosis (MS), and is associated with a higher proportion of patients reaching ... Read more

February 6, 2017February 6, 2017

Switching From Gilenya to Lemtrada Seen to Trigger Disease Activity in Some MS Patients

News

Switching from Gilenya (fingolimod) to Lemtrada (alemtuzumab) triggers significant and unexpected disease activity in some patients with multiple sclerosis (MS), according to a study published in ... Read more

February 3, 2017February 3, 2017

Clinical Trial Supports Stem Cell Transplants to Treat RMS Patients with High Disease Activity

News

A newly concluded clinical trial gives scientific evidence of the benefits that a stem cell transplant holds for multiple sclerosis (MS) patients who fail to respond to medications — with researchers calling the ... Read more

January 19, 2017January 19, 2017

Siemens Healthineers and Biogen to Enhance MRI’s Ability to Help MS Patients

News

Siemens Healthineers and Biogen will collaborate to develop new magnetic resonance imaging (MRI) applications that can quantify key markers of multiple sclerosis (MS). “By bringing together the ... Read more

December 13, 2016December 13, 2016

Zinbryta Approved in Canada as Once-Monthly Treatment for Relapsing MS

News

Health Canada has approved Zinbryta (daclizumab) as a treatment for adults with active relapsing-remitting multiple sclerosis (RRMS), Biogen and AbbVie announced. Zinbryta is a long-acting injection therapy, self-administered monthly, for patients who ... Read more

October 6, 2016October 6, 2016

Tysabri May Be More Effective Than Gilenya at Reducing Disease Activity in MS Patients, Study Says

News

An indirect comparison of results from randomized clinical trials in relapsing-remitting multiple sclerosis (RRMS) patients suggests that Tysabri (natalizumab) is more effective than Gilenya (fingolimod) at ... Read more

September 23, 2016September 26, 2016

#ECTRIMS2016 – Primary Progressive MS Patients May Soon Have Ocrevus as Treatment

News

Results from the ORATORIO trial, exploring Ocrevus (ocrelizumab) for the treatment of primary progressive forms of multiple sclerosis (MS), showed that the drug stopped disease progression ... Read more

May 17, 2016June 21, 2016

Study of Immune System Response to Viral Infection Revives Possibility of Link Between MS and Viruses

News

Researchers investigating immune B-cell response to the Epstein-Barr virus (EBV) and cytomegalovirus (CMV) found that it may correlate with the amount of brain-specific B-cells in the blood ... Read more

April 5, 2016April 5, 2016

New Clinical Trial Data on Experimental MS Therapeutic Vaccine, Xemys, Released

News

PJSC Pharmsynthez, a pharmaceutical company based in Russia, recently announced completed follow-up findings and data analysis from a Phase 2a proof-of-concept clinical trial of its novel therapeutic ... Read more